Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Total Liabilities (2016 - 2025)

Spero Therapeutics' Total Liabilities history spans 10 years, with the latest figure at $9.9 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 84.64% year-over-year to $9.9 million; the TTM value through Dec 2025 reached $9.9 million, down 84.64%, while the annual FY2025 figure was $9.9 million, 84.64% down from the prior year.
  • Total Liabilities reached $9.9 million in Q4 2025 per SPRO's latest filing, down from $27.7 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $83.4 million in Q1 2022 to a low of $9.9 million in Q4 2025.
  • Average Total Liabilities over 5 years is $48.4 million, with a median of $45.9 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: skyrocketed 286.64% in 2021, then plummeted 84.64% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $82.8 million in 2021, then plummeted by 40.97% to $48.9 million in 2022, then soared by 54.49% to $75.5 million in 2023, then fell by 14.67% to $64.4 million in 2024, then tumbled by 84.64% to $9.9 million in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Total Liabilities are $9.9 million (Q4 2025), $27.7 million (Q3 2025), and $29.3 million (Q2 2025).